A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
Receive an email update when we add a new CANCER IMMUNOTHERAPY article.
The Latest on: Cancer immunotherapy
via Google News
The Latest on: Cancer immunotherapy
- Astellas Acquires Collaboration Partner Potenza Therapeutics, Adding Cancer Immunotherapy Programs on December 17, 2018 at 7:15 am
Astellas Pharma has acquired Potenza Therapeutics for up to $404.7 million in a deal that bolsters the buyer’s cancer immunotherapy pipeline—more than three years after the companies launched an immun... […]
- First Line Immunotherapy Combination Fails to Improve Overall Survival in Lung Cancer: Study on December 15, 2018 at 8:37 pm
In unselected patients with lung cancer, first line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival, according to late breaking result... […]
- Cancer Immunotherapy Drug Discovery Outsourcing Market is grow with 14.0% CAGR during the forecast time period 2018-2026 on December 14, 2018 at 3:21 am
The global cancer immunotherapy drug discovery outsourcing market size is anticipated to around USD 1.8 billion by 2026, this market is anticipated to grow with 14.0% CAGR during the forecast time per... […]
- Can we teach the immune system to fight cancer? on December 13, 2018 at 3:52 pm
T cells attacking cancer (royaltystockphoto). When telling the story of immunotherapy and cancer and how the two battle it out, it’s awfully challenging not to pull out the old A Tale of Two ... […]
- First line immunotherapy combination fails to improve overall survival in lung cancer on December 13, 2018 at 9:24 am
First line immunotherapy with durvalumab or the combination of durvalumab and tremelimumab does not improve overall survival in unselected patients with lung cancer, according to late breaking ... […]
- Targeting cancer with sugar-powered immunotherapy on December 12, 2018 at 7:23 am
Over the last few decades, researchers tinkering with molecules that turn an immune cell on and off have created a revolutionary approach to fighting cancer. Instead of taking aim at the tumor ... […]
- Global Dendritic Cell Cancer Immunotherapy Vaccine Market Sales Dosage Price and Clinical Trials Outlook 2024 on December 6, 2018 at 1:09 am
Download Report: https://www.kuickresearch.com/report-global-dendritic-cell-cancer-vaccine-market-dosage-price-and-clinical-trials-outlook-2024.php Conventional therapies like surgery, radiotherapy an... […]
- Dr. Arkenau on the Potential of Immunotherapy in Gastric Cancer on December 5, 2018 at 3:04 pm
Hendrik-Tobias Arkenau, MD, PhD, medical director, Sarah Cannon Research Institute UK, discusses the potential of immunotherapy in gastric cancer. Immunotherapy has shown benefit in some patients with ... […]
- New Cancer Immunotherapy Approach Turns Immune Cells into Tiny Anti-Tumor Drug Factories on December 4, 2018 at 1:21 pm
Cancer immunotherapy — efforts to better arm a patient’s own immune system to attack tumors — has shown great potential for treating some cancers. Yet immunotherapy doesn’t work for everyone, and some ... […]
via Bing News